Understanding resistance in multiple myeloma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on patients diagnosed with multiple myeloma (MM) at specialized oncology centers in Northwestern France. It aims to gather comprehensive data on the biological mechanisms of therapeutic resistance, as well as predictors of this resistance, through continuous follow-up and collection of socio-economic, medical, and quality of life information. Participants will also provide blood samples for analysis to identify potential biomarkers and improve diagnostics. The study includes all patients over 18 years old diagnosed with MM, ensuring a diverse cohort for better insights.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient consulting due to the discovery or recurrence of MM according to international diagnostic criteria (IMWG 2014)
* Patient having consented to participate in the study and his/her biocollection
* Patient affiliated to or benefiting from a social security scheme or similar

Exclusion Criteria:

* Minors
* Major under guardianship or curatorship
* Protected persons.
* Pregnant or breast-feeding women
* Persons benefiting from the AME

Where it's running

• La Roche sur Yon Hospital Departmental
  La Roche-sur-Yon, France Recruiting
• Nantes University Hospital
  Nantes, France Recruiting

Study contacts

• Principal investigator: Cyrille TOUZEAU, PU — Nantes University Hospital
• Study coordinator: Cyrille TOUZEAU, PU
• Email: cyrille.touzeau@chu-nantes.fr
• Phone: 02 40 08 32 71

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• 6MW5311 in adults with relapsed or refractory blood cancers

  This study tests increasing doses of 6MW5311 in adults with multiple myeloma, AML, or CMML to see if it is safe and tolerable and to find a suitable dose for later studies.

  Recruiting Phase 1 Mabwell (Shanghai) Bioscience Co., Ltd. · Shanghai, Shanghai Municipality · NCT07914556

• Tailored exercise program to improve quality of life for adults with hematologic cancers

  This pilot trial tests a personalized 16-week exercise program to see if it’s feasible and helpful for adults with acute myeloid leukemia, lymphoma, or multiple myeloma after first-line treatment.

  Recruiting Gruppo Italiano Malattie EMatologiche dell'Adulto · Roma, Rm and 2 other locations · NCT07912684

• Aspirin vs. rivaroxaban for blood clot prevention in newly diagnosed multiple myeloma

  In newly diagnosed multiple myeloma patients on IMiD-based therapy, this study tests whether aspirin or rivaroxaban is better at preventing blood clots.

  Recruiting Phase 4 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07907211

• Exercise phenotyping before chemotherapy in newly diagnosed multiple myeloma

  This observational study tests whether some newly diagnosed multiple myeloma patients with normal resting heart function already show limited exercise capacity, and whether that limitation relates to subtle heart tissue changes and future heart-related outcomes.

  Recruiting Technical University of Munich · Munich, Bavaria · NCT07851493

• SMS text check-ins to track symptoms for people with plasma cell disorders

  This study tests whether daily SMS symptom prompts are feasible and acceptable for adults starting treatment for multiple myeloma or AL amyloidosis.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT07850284

• Cevostamab with Pomalidomide and Dexamethasone after BCMA-directed CAR T therapy in multiple myeloma

  This study tests if Cevostamab combined with pomalidomide and dexamethasone can help people with multiple myeloma who have already had CAR T therapy and several prior treatments.

  Recruiting at 5 sites Phase 2 Hoffmann-La Roche · Nuremberg, Bavaria and 4 other locations · NCT07825064

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.